The State Intellectual Property Office of the People’s Republic of China has issued a new Chinese patent which provides composition of matter protection for Rib-X’s novel oxazolidinone antibiotic, radezolid.
Rib-X has established a broad patent portfolio related to radezolid, including the issuance of composition of matter for radezolid in the US. The company anticipates issuance of additional patents in all major and emerging markets.
Susan Froshauer, president and CEO of Rib-X Pharmaceuticals, said: “This Chinese patent strengthens Rib-X’s existing intellectual property portfolio and underscores our ability to successfully design and develop antibiotics that overcome resistant bacteria.
“China is the world’s largest emerging pharmaceutical market, and the issuance of this patent enhances Rib-X’s commercial opportunities in this important region of the world.”